Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Daiichi Sankyo, UCB to Jointly Commercialize Epilepsy Drug Lacosamide
Daiichi Sankyo and Brussels-based UCB Biopharma said on November 28 that they have entered into a joint commercialization pact for the antiepileptic treatment lacosamide in Japan, looking to file for regulatory approval by the end of 2015. Under the deal,…
To read the full story
Related Article
BUSINESS
- SSP Looks to Broaden Switch OTC Portfolio under New President
April 13, 2026
- Nippon Shinyaku, xFOREST Ink RNA-Targeting Small Molecule Research Pact
April 13, 2026
- OTC-Like Drug Reform Seen Adding 190 Billion Yen to Japan OTC Market by 2040: Fuji Keizai
April 13, 2026
- AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances
April 13, 2026
- MSD Japan Eyes Up to 8 Approvals, 8-Plus Filings under New Chief
April 10, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…